Overview and Mechanism of Action of Bempedoic Acid (Nilemdo)

Release date: 2026-07-03 16:34:29     Recommended: 6

Overview and Mechanism of Action of Bempedoic Acid (Nilemdo)

Bempedoic acid (Nilemdo) is a novel oral lipid-lowering agent specifically indicated for reducing blood levels of "bad" cholesterol (low‑density lipoprotein cholesterol, LDL‑C). Its active moiety, bempedoic acid, is inactive in the circulation and requires hepatic uptake and conversion to its active form to exert its effects. The drug selectively inhibits ATP citrate lyase, a key enzyme in the cholesterol synthesis pathway, within the liver, thereby decreasing de novo cholesterol synthesis; concurrently, this process upregulates low‑density lipoprotein receptors on the hepatocyte surface, accelerating the clearance of LDL‑C from the bloodstream. This dual mechanism enables bempedoic acid (Nilemdo) to effectively lower LDL‑C levels and, consequently, reduce the risk of atherosclerotic cardiovascular events. Compared with classical statins, bempedoic acid acts at a different target upstream in the cholesterol synthesis pathway, offering a new therapeutic option for patients who have an inadequate response to statins or are statin‑intolerant. The product should be used in conjunction with dietary control, and its lipid‑lowering effect is dose‑dependent; the recommended fixed dose is administered once daily, facilitating long‑term compliance.

Indications and Target Populations for Bempedoic Acid (Nilemdo)

Bempedoic acid (Nilemdo) is indicated for two categories of adult patients: ① those with primary hypercholesterolaemia or mixed dyslipidaemia – i.e., lipid elevations due to genetic or metabolic factors, requiring pharmacological therapy in addition to dietary intervention; and ② patients with established cardiovascular disease (e.g., coronary heart disease, history of stroke) or with multiple risk factors (e.g., diabetes, hypertension) placing them at high cardiovascular risk. Specific treatment conditions include: when a patient is already on statin therapy (e.g., simvastatin) but LDL‑C remains above target, bempedoic acid (Nilemdo) may be added to enhance efficacy; if the patient cannot tolerate any dose of a statin due to myalgia, elevated liver enzymes, or other reasons, or has contraindications to statins, bempedoic acid (Nilemdo) may be used alone or in combination with other lipid‑lowering agents such as fenofibrate. The drug does not replace all the benefits of statins but provides a flexible lipid‑lowering strategy in clinical practice, particularly suitable for mixed hyperlipidaemia and for secondary prevention populations requiring additional LDL‑C reduction.

Preconditions for Use of Bempedoic Acid (Nilemdo)

Before initiating therapy with bempedoic acid (Nilemdo), patients must actively inform their physician of the following personal history: previous episodes of gout (as the drug may increase serum uric acid); presence of severe renal impairment (significantly reduced estimated glomerular filtration rate); and presence of severe hepatic disease or persistently abnormal liver enzymes. Physicians typically perform baseline blood tests, including liver function (ALT/AST), renal function (creatinine, urea nitrogen), and uric acid levels, to assess safety prior to treatment. If the patient is already taking a statin, special attention should be paid to unexplained muscle symptoms (pain, tenderness, weakness); any such symptoms should be reported immediately, as combination therapy may increase the risk of myopathy. In addition, if concomitant use of a fibrate is planned, the physician will monitor changes in triglycerides and high‑density lipoprotein cholesterol at 4 weeks after treatment initiation and periodically thereafter to adjust the regimen. All warning information is intended to prevent serious adverse events and ensure individualised treatment.